The Antibiotic Kitasamycin—A Potential Agent for Specific Fibrosis Preventing Therapy after Fistulating Glaucoma Surgery?

Katharina A. Sterenczak, Georg Fuellen, Anselm Jünemann, Rudolf F. Guthoff, Oliver Stachs, Thomas Stahnke

Open source

DOI
10.3390/pharmaceutics15020329
Published
2023-01-18
Container
Pharmaceutics
Publisher
MDPI AG
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3390/pharmaceutics15020329,
  title = {The Antibiotic Kitasamycin—A Potential Agent for Specific Fibrosis Preventing Therapy after Fistulating Glaucoma Surgery?},
  author = {Katharina A. Sterenczak and Georg Fuellen and Anselm Jünemann and Rudolf F. Guthoff and Oliver Stachs and Thomas Stahnke},
  year = {2023},
  journal = {Pharmaceutics},
  doi = {10.3390/pharmaceutics15020329},
  url = {https://doi.org/10.3390/pharmaceutics15020329}
}

RIS

TY  - JOUR
TI  - The Antibiotic Kitasamycin—A Potential Agent for Specific Fibrosis Preventing Therapy after Fistulating Glaucoma Surgery?
AU  - Katharina A. Sterenczak
AU  - Georg Fuellen
AU  - Anselm Jünemann
AU  - Rudolf F. Guthoff
AU  - Oliver Stachs
AU  - Thomas Stahnke
PY  - 2023
JO  - Pharmaceutics
DO  - 10.3390/pharmaceutics15020329
UR  - https://doi.org/10.3390/pharmaceutics15020329
ER  - 

APA

Sterenczak, K. A., Fuellen, G., Jünemann, A., Guthoff, R. F., Stachs, O., & Stahnke, T. (2023). The Antibiotic Kitasamycin—A Potential Agent for Specific Fibrosis Preventing Therapy after Fistulating Glaucoma Surgery?. Pharmaceutics. https://doi.org/10.3390/pharmaceutics15020329

Source records